An In Vitro Screening Tool for Predicting Clinical CYP3A4 Induction

Induction‐mediated drug‐drug interactions need to be carefully characterized in vitro for drug candidates in order to determine and/or predict their induction potential in patients. Currently, both the FDA and EMA recommend using primary human hepatocytes as an in vitro test system for this purpose. In this poster, Corning HepatoCells (derived from primary human hepatocytes) were evaluated for its applicability as an in vitro screening tool for predicting clinical CYP3A4 inducers.